MCE 免疫检查点蛋白 Immune Checkpoint Proteins_第1页
MCE 免疫检查点蛋白 Immune Checkpoint Proteins_第2页
MCE 免疫检查点蛋白 Immune Checkpoint Proteins_第3页
MCE 免疫检查点蛋白 Immune Checkpoint Proteins_第4页
MCE 免疫检查点蛋白 Immune Checkpoint Proteins_第5页
已阅读5页,还剩3页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

www.MedChemEInhibitors • ScreeningLibraries • Proteins免疫检查点蛋白免疫检查点(ImmuneCheckpoints)分子是对免疫应答发挥抑制或刺激作用的配体-受体对,它们在维持免疫稳态和免疫耐受中起着重要的调节作用。大多数被报道的免疫检查点蛋白在适应性免疫系统(特别是T细胞)和先天免疫系统的细胞上表达。一些肿瘤细胞通过结合共抑制受体分子,限制正常的抗肿瘤免疫反应,从而帮助免疫逃逸。癌症的免疫检查点治疗策略包括了靶向这些调控途径,以恢复免疫细胞的抗肿瘤功能。目前,研究最广泛的抑制性免疫检查点包括CTLA-4和PD-1/PD-L1等[7][8]。A2aRVISTAAdenosineB7-H3PDL1/PDL2A2aRGalectin-9??CD80/CD86PD1TIM-3CD80/CD86CTLA-4OX40LCD28T-CellCD40OX40CD40LB7RP1ICOSCD70CD27HVEMBTLAAPCorLAG-3TumorCellTCRMHCl/llKIRGITRGITRL4-1BBCD226/TIGIT4-1BBLCD155/CD112OtherpotentialpathwaysIL10 CD47IDO TLRTGF-β ArginaseInhibitoryPathwaysStimulatoryPathwaysFigure1.常见的免疫检查点刺激途径和抑制途径[9]4MCEMasterofBioactiveMoleculesCat.No.ProductNameSpeciesSourceTagHY-P70691CTLA-4HumanMammalianCellsC-GSTHY-P70632PD-L1MouseMammalianCellsC-HisHY-P7395PD-1HumanMammalianCellsC-hFcHY-P70482TIM3HumanMammalianCellsC-HisHY-P70722LAG-3HumanMammalianCellsC-HisHY-P70624TIGITHumanMammalianCellsC-HisHY-P7327CD276/B7-H3HumanMammalianCellsC-HisHY-P74464-1BBL/TNFSF9MouseMammalianCellsN-HisHY-P7144CD40L/CD154/TRAPHumanE.coliTag-freeHY-P70652CD276/B7-H3HumanMammalianCellsC-HisHY-P7678BTLA/CD272HumanMammalianCellsC-HisHY-P7685BTN3A3HumanMammalianCellsC-HisHY-P70535Galectin-9HumanMammalianCellsC-HisHY-P7366HVEMHumanSf9insectCellsC-hFcHY-P70494Nectin-1HumanMammalianCellsC-HisHY-P70807PVR/CD155HumanMammalianCellsC-HisHY-P73370PD-L2RatMammalianCellsC-hFcHY-P77879VISTAHumanMammalianCellsC-hFcHY-P75610CD137/4-1BBCanineMammalianCellsC-HisHY-P7394OX40/TNFRSF4HumanMammalianCellsC-HisHY-P77457OX40Ligand/TNFSF4CynomolgusMammalianCellsN-mFcHY-P73499CD40HumanMammalianCellsC-HisHY-P73306Nectin-3HumanMammalianCellsC-HisHY-P71248PVRIGHumanMammalianCellsC-mFcHY-P76070SIRPalphaMouseMammalianCellsC-HisHY-P73121IDOHumanE.coliTag-freeHY-P76396ICOSHumanMammalianCellsC-His-hFcHY-P77575ICOSLGCynomolgusMammalianCellsC-HisHY-P72353CD28Human/CynomolgusMammalianCellsC-Fc-AviHY-P72033LIGHTHumanMammalianCellsN-hFc-MycHY-P73076GITRHumanMammalianCellsC-HisHY-P7318GITRL/AITRLHumanE.coliTag-freeHY-P72887CD200HumanMammalianCellsC-hFcHY-P76780CD200R1CynomolgusMammalianCellsC-His5www.MedChemEInhibitors • ScreeningLibraries • ProteinsMCE重组蛋白MCE重组蛋白产品种类丰富,涵盖细胞因子、病毒蛋白、免疫检查点蛋白、CAR-T蛋白、CD抗原、受体蛋白、生物素标记蛋白、GMP级蛋白、酶等多种分类,可用于人、病毒、小鼠、大鼠、猴、猪、狗、牛、羊、兔、猫、非洲爪蟾等多个物种不同研究领域的生物学研究,包括蛋白结构研究、免疫检测试剂、重组蛋白药物、诊断试剂开发、抗体药物靶点、CAR-T细胞治疗靶点、Fc受体、流感病毒蛋白和细胞因子等热门研究领域。MCE因高品质的产品和优质的售前售后服务,成为全球数百万计的科学家和技术人员值得信赖的实验伙伴。产品种类丰富: 细胞因子和生长因子、免疫检查点蛋白、CAR-T相关蛋白、CD抗原、受体蛋白、酶&调节子、补体系统蛋白、病毒类蛋白、生物素标记蛋白、荧光标记蛋白、GMP级蛋白,泛素相关蛋白等产品物种多样性:人、病毒、小鼠、大鼠、猴、猪、狗、牛、羊、兔、猫、非洲爪蟾、细菌、真菌等低内毒素水平: LAL法验证,内毒素含量低于绝大多数供应标准高纯度: SDS和HPLC检测验证高生物活性: 相关体内/体外生物学实验测定稳定的一致性: 多批次检测数据确认规格齐全: 满足客户的多种预分装规格高纯度ThepurityofhumanBMP-2isgreaterthan95%asanalyzedbySDSunderreducing(R)andnon-reducing(N)condition.kDa M R 120806040302010卓越的批间稳定性TheED50ofMCEhumanVEGF165fromthreedifferentLotsaresimilar.1.0Lot1nm)0.8Lot20.6Lot3(4900.4OD0.2Net0.01010101010VEGF165,Human(ng/mL)

高活性HumanGM-CSFstimulatescellproliferationofTF-1cellswithanED50oflessthan0.5ng/mL.2.0(490nm)1.51.0NetOD0.50.010101010101010GM-CSF,Human(ng/mL)竞品对比TheED50ofhumanVEGF165fromMCE’seachLotislowerthanofCompetitorP.1.0BrandPnm)0.8Lot20.6Lot3(4900.4OD0.2Net0.010-210-1101010VEGF165,Human(ng/mL)MCEMasterofBioactiveMoleculesPublicationsCitingUseofMCEProductsNature.2023Jun;618(7964):374-382.Nature.2023Jun;618(7966):862-870.Nature.2023Jun;618(7965):590-597.Nature.2023Jun;618(7963):180-187.Nature.2023May;617(7962):818-826Science.2023Jun9;380(6649):eabo2296.Science.2022Dec2;378(6623):eabo5503.Science.2022Nov18;378(6621):eabq7361.Science.2022Oct14;378(6616):eabq0132.Science.2022Jul8;377(6602):eabg9302Cell.2023Jun22;186(13):2823-2838.e20.Cell.2023May11;186(10):2144-2159.e22.Cell.2023Mar30;186(7):1352-1368.e18.Cell.2023Mar2;186(5):1026-1038.e20.Cell.2023Feb16;186(4):850-863.e16MCEGlobalPartnersMCEMasterofBioactiveMolecules客户验证诱导小鼠肺成纤维细胞纤维化TGF-β1(HY-P7117)刺激原代小鼠肺成纤维细胞,通过qRT-PCR和WB检测PTPN13和NOX4表达水平,确定其与细胞纤维化密切相关[41]。ControlTGF-β1PTPN13NOX4expression10**expression8**86mRNA6mRNA44Relative2Relative200

ControlTGF-β1ControlTGF-β1CollagenI139kDaPTPN13310kDaα-SMA42kDaNOX455kDaGAPDH37kDaGAPDH37kDa构建肾脏类器官从小鼠肾脏组织中提取细胞,利用微流体技术结合3D打印机制作类器官珠,辅以Noggin(HY-P7086)、R-spondin-1(HY-P7114)、FGF-4(HY-P7014)、FGF-basic(HY-P7066)、SB-431542(HY-10431)、Laduviglusib(HY-10182)培养,7天后,得到数千个大小、形状和成分具有高度重复性的肾脏类器官[42]。OrganoidGeneratingKidneyOrganoidBeadsKidneyOrganoidsMatrigel+CellsDay1Day7QDs/Drugs7days24hrsOrganoidCulturingCulturingHighThroughputScreeningOil4°CKidneyOrganoidBeads200μm200μmCultureDish37°CIFN-γ诱导蛋白16(IFI16)的积累通过Westernblotting检测IFN-γ(HY-P7025)处理人肺腺癌上皮(A549)细胞18小时后,蛋白16(IFI16)的积累,通过免疫染色检测IFN-γ诱导16小时后IFI16的细胞定位[43]。HumanIFN-γ(ng/mL)0505001000IFI16—100(kDa)—70β-actin—40

NegativeControl IFN-γ(500ng/mL)DAPI/IFI1617www.MedChemEInhibitors • ScreeningLibraries • Proteins更多文献引用情况文献产品名称货号AdvFunctMater.10March2022.IFN-gamma;IL-13;IL-4HY-P7071;HY-P7076A;HY-P7080SignalTransductTargetTher.2022Mar11;7(1):83.AXLHY-P7622SignalTransductTargetTher.2022Jan7;7(1):6.HABP2HY-P70832NatMicrobiol.2021Jul;6(7):932-945.IFN-gammaHY-P7025AdvSci(Weinh).2021Dec;8(24):e2100808.NPYHY-P71063CellDeathDiffer.2022Apr;29(4):818-831.FGFbasic;FGF-2HY-P7004;HY-P7066NatCommun.2022Feb23;13(1):1017.TGFbeta1HY-P7118JImmunotherCancer.2022Feb;10(2):e003716.IL-2HY-P7077Small.2020Jun;16(22):e2001371.FGF-4;FGF-2;Noggin;RSPO1HY-P7014;HY-P7066;HY-P7086;HY-P7114Biomaterials.2021Jan;265:120392.GM-CSFHY-P7069RedoxBiol.2021Jul;43:101994.IL-6HY-P7103ATheranostics.2022Jan1;12(3):1097-1116.IGF2HY-P7019Theranostics.2022Jan1;12(2):747-766.IFN-gammaHY-P7025;HY-P7071Theranostics.2021May13;11(14):7110-7125.TGFbeta1HY-P7118Theranostics.2021Jan9;11(7):3244-3261.TGFbeta1HY-P7117ActaPharmSinB.2020Sep;10(9):1619-1633.M-CSFHY-P7085JExpClinCancerRes.2020Jun23;39(1):119.IL-6RalphaHY-P7223BiosensBioelectron.2020Sep19;173:112619.IFN-gammaHY-P7025CardiovascDiabetol.2022Feb15;21(1):25.AsprosinHY-P7612JControlRelease.IL-4;M-CSF;TNF-alpha;HY-P7080;HY-P7085;HY-P7090;2021Jul26;S0168-3659(21)00383-7.MIP-1alpha;GM-CSFHY-P7255;HY-P7361CellRep.2022Feb1;38(5):110319.TNFalpha;GMPIL-6HY-P70426;HY-P7044GCellRep.2021Jan5;34(1):108576.IL-1RAHY-P7029ACellRep.2020Jan7;30(1):98-111.e5.FGFbasic;EGF;VEGF121HY-P7004;HY-P7109;HY-P7420ActaBiomater.2020Jan1;101:152-167.DKK-1HY-P7155ACancerLett.2022Mar9;215629.BDNFHY-P7116ACancerLett.13July2021.FGFbasicHY-P7004CellDeathDis.2021Apr14;12(4):397.NRG1-beta1HY-P7365CellDeathDis.2021Nov27;12(12):1113.FGFbasicHY-P7004CellDeathDis.2021Oct12;12(10):934.M-CSFHY-P7085CellDeathDis.2020May7;11(5):323.TNF-alphaHY-P7416CellDeathDis.2020Nov4;11(11):950.Insulin;FGFbasic;EGFHY-P0035;HY-P7004;HY-P7109JNeuroinflammation.2019Nov26;16(1):234.IL-1RAHY-P702918MCEMasterofBioactiveMoleculesReferences:Jun-MingZhang.Cytokines,inflammation,andpain.IntAnesthesiolClin.2007Spring;45(2):27-37.PedroBerraondo,etal.Cytokinesinclinicalcancerimmunotherapy.BrJCancer.2019Jan;120(1):6-15.Ferreira,Vinicius,etal.CytokinesandInterferons:TypesandFunctions.InAutoantibodiesandCytokines,editedbyWahidKhan.London:IntechOpen,2018.XiaochenRen,etal.GrowthFactorEngineeringStrategiesforRegenerativeMedicineApplications.FrontBioengBiotechnol.2019;7:469.StoneWL,LeavittL,VaracalloM.Physiology,GrowthFactor.In:StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2022Jan.OzlemGuzeloglu-Kayisli,HughSTaylor,etal.Theroleofgrowthfactorsandcytokinesduringimplantation:endocrineandparacrineinteractions.SeminReprodMed.2009Jan;27(1):62-79.YapingZhang,etal.FunctionsofImmuneCheckpointMoleculesBeyondImmuneEvasion.AdvExpMedBiol.2020;1248:201-226.XingHe,etal.Immunecheckpointsignalingandcancerimmunotherapy.CellResearch.2020;30:660-669.Marin-AcevedoJA,etal.Nextgenerationofimmunecheckpointtherapyincancer:newdevelopmentsandchallenges.JHematolOncol.2018;11(1):39.ChristopherDeRenzo,etal.GeneticModificationStrategiestoEnhanceCARTCellPersistenceforPatientsWithSolidTumors.FrontImmunol.2019Feb15;10:218.MEssand,etal.GeneticallyengineeredTcellsforthetreatmentofcancer.JInternMed.2013Feb;273(2):166-81.ZhenguangWang,etal.NewdevelopmentinCAR-Tcelltherapy.JHematolOncol.2017;10:53.LekhaMikkilineni,etal.ChimericantigenreceptorT-celltherapiesformultiplemyeloma.Blood.2017Dec14;130(24):2594-2602.JuliusM.Cruse,RobertE.Lewis,andHuanWang.CLUSTEROFDIFFERENTIATION(CD)ANTIGENS.ImmunologyGuidebook.2004:47-124.TomasKalina,etal.CDMaps-DynamicProfilingofCD1-CD100SurfaceExpressiononHumanLeukocyteand[16]LymphocyteSubsets.FrontImmunol.2019Oct23;10:2434.DarioGosmann,AngelaM.Krackhardt,CalogeroD’Alessandria,etal.P.romiseandchallengesofclinicalnon-invasiveT-celltrackingintheeraofcancerimmunotherapy.EJNMMIRes.2022Jan31;12(1):5.MareeS.etal.FcReceptors.AdvExpMedBiol.2008;640:22-34.SanaeBenMkaddem,etal.UnderstandingFcReceptorInvolvementinInflammatoryDiseases:FromMechanismstoNewTherapeuticTools.FrontImmunol.2019Apr12;10:811.D.Mancardi.FcReceptor-DependentImmunity.ReferenceModuleinBiomedicalSciences.2014:B978-0-12-801238-3.00119-7.Mårtensson,A.DevelopmentofanAntigen-independentAffinityAssaytoStudytheBindingofIgGtoFcGammaReceptors.2012.S.Xiong,etal.HumanImmuneSystem,Editor(s):Andersrahme,ComprehensiveBiomedicalPhysics,Elsevier,2014,Pages91-114.Carl-HenrikHeldin,etal.SignalsandReceptors.ColdSpringHarbPerspectBiol.2016Apr;8(4):a005900.RitaSantos,etal.Acomprehensivemapofmoleculardrugtargets.NatRevDrugDiscov.2017Jan;16(1):19-34..

Young-SunLee,etal.Anti-InflammatoryEffectsofGLP-1-BasedTherapiesbeyondGlucoseControl.MediatorsInflamm.2016;2016:3094642.PeterK.etal.Enzymes:principlesandbiotechnologicalapplications.EssaysBiochem.2015Nov15;59:1-41.AntonioBlanco,etal.Enzymes,Editor(s):AntonioBlanco,Gustavolanco,MedicalBiochemistry,AcademicPress,2017,Pages153-175.CooperGM.TheCell:AMolecularApproach.2ndedition.Sunderland(MA):SinauerAssociates;2000.LiubovPoshyvailo.Modellingandsimulationsofenzyme-catalyzedreactions.NationalUniversityof“Kyiv-MohylaAcademy”FacultyofNaturalSciences,DepartmentofPhysicsandMathematics.2015.JanewayCAJr,etal.Thecomplementsystemandinnateimmunity.Immunobiology:TheImmuneSysteminHealthandDisease.5thedition.NewYork:GarlandScience;2001.GuillerminaGirardi,etal.EssentialRoleofComplementinPregnancy:FromImplantationtoParturitionandBeyond.FrontImmunol.2020;11:1681.LanKNguyen,etal.Whenubiquitinationmeetsphosphorylation:asystemsbiologyperspectiveofEGFR/MAPKsignaling.CellCommunSignal.2013Jul31;11:52.GuoHJ,etal.Biochemistry,Ubiquitination.In:StatPearls[Internet].TreasureIsland(FL):StatPearlsPublishing;2022Jan.FuShang,etal.Ubiquitin-proteasomepathwayandcellularresponsestooxidativestress.FreeRadicBiolMed.2011Jul1;51(1):5-16.Hochstrasser,M.Originandfunctionofubiquitin-likeproteins.Nature.2009Mar26;458(7237):422-9.ViralStructuralProteins.NCBI.Literature.MeSHDatabase.Yearintroduced:1990.JenniferLouten.VirusStructureandClassification.EssentialHumanVirology.2016:19-29.GelderblomHR.StructureandClassificationofViruses.In:BaronS,editor.MedicalMicrobiology.4thedition.Galveston(TX):UniversityofTexasMedicalBranchatGalveston;1996.Chapter41.Chand

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

最新文档

评论

0/150

提交评论